January 8, 2013
US demand for influenza vaccines will remain high in the coming
decade, following a post-flu pandemic spike, predicts business
intelligence provider GlobalData in its latest epidemiology report,
which finds that seasonal influenza vaccine demand will increase from
the 142 million expected for 2012 to 158 million in 2022, representing
an annual growth rate (AGR) of 1.2%.